This company holds an exclusive license to a plant cell-extraction and replication technology for producing cannabinoids (THC and CBD) in a bioreactor setting — without growing the whole plant — covering North America, Central America, and the Caribbean. The licensed technology is designed to replicate the flavor, aroma, and potency of cannabis in a laboratory environment, and the company claims it could produce cannabis-derived material at under $250 per pound, compared to $680–$950 per pound for indoor grows and $325–$420 for greenhouse grows in California. The company does not produce or sell cannabinoids itself; its intended business model is to sublicense the technology to third-party cannabis operators, who would fund and build their own production facilities using the licensed process in exchange for paying royalties. One existing sublicense agreement with Integrity Cannabis Solutions illustrates the intended structure, providing for an 8% royalty on wholesale CBD product revenue, though this agreement is not yet effective. In practice, the company is pre-revenue with two employees, no commercial agreements in place, and a working capital deficit of nearly $10M. The company owes $3.5M to Cell Science, its licensor, and is attempting to raise up to $20M through convertible notes, of which only $830K had been sold as of December 2023. The technology has not been scaled to commercial production, cost estimates remain unproven, and state cannabis regulations are generally written around live-grow plant production, creating additional regulatory hurdles for bioreactor-based production.